Incurred sample reanalysis [Regulatives / Guidelines]

posted by The Outlaw Torn – Europe, 2013-04-10 10:40 (4828 d 00:19 ago) – Posting: # 10387
Views: 17,514

Dear Ohlbe,

❝ The long-term stability is not the only issue anyway: back-conversion during sample processing can be of greater concern. And are you sure you know all metabolites ? EMA got trapped in their recommendations on clopidogrel1


I just happened to be cruising by this joint looking for anything new on ISR. Glad to see you tapping this subject. You answered a lot of my questions, except I'm not sure I understand what you mean by the EMA getting trapped. Do you mean that there are ways around justifying clopidogrel, or other drugs known for back-conversion, that EMA hadn't considered (the paper you quoted where the authors found a way of controlling back-conversion)? Is that it? If that's not the case, mind expanding on this while I sit back and have a drink?

Thanks,
Outlaw

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
239 visitors (0 registered, 239 guests [including 17 identified bots]).
Forum time: 11:00 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5